<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03399084</url>
  </required_header>
  <id_info>
    <org_study_id>1637 FCM_1</org_study_id>
    <nct_id>NCT03399084</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia</brief_title>
  <official_title>An Open-label, Randomized, Parallel, Bioequivalence Study of 750 mg Intravenous Single Dose Ferric Carboxymaltose Versus Injectafer® (750 mg Iron/15 mL Colloidal Solution) in Adult Patients With Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate bioequivalence of two formulations of Ferric Carboxymaltose as
      measured by serum total iron, in adult patients with iron deficiency anemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence assessed by maximum serum concentration (Cmax)of serum total iron.</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Measured by Cmax - The maximum plasma concentration of iron</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence assessed by area under the serum concentration-time curve (AUC) of serum total iron.</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Plasma Pharmacokinetics (PK) of study medication: Area Under the Plasma Concentration-time Curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of serum transferrin-bound iron.</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Plasma Pharmacokinetics (PK): The maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax) of serum total iron and transferrin-bound iron</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Plasma Pharmacokinetics (PK): Time of Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of serum transferrin-bound iron</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Plasma Pharmacokinetics (PK): area under the serum concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal rate constant of serum total iron and transferrin-bound iron</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Plasma Pharmacokinetics (PK): Apparent terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of serum total iron and transferrin-bound iron</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Plasma Pharmacokinetics (PK): Apparent terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (CL) of serum total iron and transferrin-bound iron after intravenous dosing</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Plasma Pharmacokinetics (PK): Systemic clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state of serum total iron and transferrin-bound iron following intravenous dosing</measure>
    <time_frame>Up to 7 Days</time_frame>
    <description>Plasma Pharmacokinetics (PK): Volume of distribution at steady state Plasma Pharmacokinetics (PK): Volume of distribution at steady state (Vss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single dose of Ferric carboxymaltose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose (reference)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a single dose of Ferric carboxymaltose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>750 mg/15 mL</description>
    <arm_group_label>Ferric carboxymaltose (reference)</arm_group_label>
    <arm_group_label>Ferric carboxymaltose (test)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients at least 18 - 65 years of age;

          -  Patients with a body mass index (BMI) between 18.5 - 35 and with a body weight of ≥50
             kg - ≤130 kg;

        Exclusion Criteria:

          -  Patients with known hypersensitivity to ferric carboxymaltose, excipients, or similar
             product

          -  Patients with chronic kidney disease who are on dialysis of any kind.

          -  If female, is pregnant or nursing.

          -  Patients with blood loss leading to hemodynamic instability

          -  Patients with recent parenteral iron within 3 months prior to screening.

        Other inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz Sandoz</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2018</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ferric carboxymaltose</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

